Thank you.
My next question is for Dr. Forbes.
Do you have any recommendations regarding whether we should factor rare diseases into a national pharmaceutical strategy? Do you have any special policies to impact or manage rare diseases in the national pharmaceutical strategy because those medications are so expensive?